Prediction of renal and cardiometabolic outcomes in gout during urate-lowering therapy by sonography.
cardiovascular diseases
glomerular filtration rate
gout
gout suppressants
kidney function tests
ultrasonography
Journal
International journal of rheumatic diseases
ISSN: 1756-185X
Titre abrégé: Int J Rheum Dis
Pays: England
ID NLM: 101474930
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
revised:
06
09
2023
received:
15
06
2023
accepted:
21
09
2023
medline:
4
12
2023
pubmed:
3
10
2023
entrez:
3
10
2023
Statut:
ppublish
Résumé
To assess whether the extent of monosodium urate (MSU) crystal deposition estimated by ultrasound could predict renal and cardiometabolic events during urate-lowering therapy (ULT). A prospective study on gout patients from two referral centers initiating ULT who underwent baseline ultrasound and were followed for 1 year. Ultrasound scans assessed six joints for double-contour (DC) signs and tophi. A five-point change (mL/min/1.73 m One hundred sixty patients were recruited. At baseline, 81.1% of patients (n = 129) showed sonographic tophi with a mean number of 1.4 joints (±1.3) with a DC sign. At M12, 18 patients (11.3%) were lost to follow-up. The serum urate (SU) target (<6.0 mg/dL) was reached in 86 patients (69.9%). Regarding renal function, 15.9% of patients showed improvement, while in 31.0% it degraded. Fourteen new cardiometabolic events occurred in 12 patients. Neither the DC sign nor tophi showed any significant impact on the outcomes of interest. Baseline SU level was higher in those with renal improvement but not with renal decline, while achieving the SU target protected against new cardiometabolic events (HR = 0.2; 95% CI: 0.05-0.81). Sonographic MSU crystal burden was unhelpful in predicting renal and cardiometabolic events during the first year of ULT. Reaching the SU target prevented cardiometabolic events, while its benefit in preserving/improving renal function is unclear.
Identifiants
pubmed: 37786305
doi: 10.1111/1756-185X.14935
doi:
Substances chimiques
Uric Acid
268B43MJ25
Gout Suppressants
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2450-2459Subventions
Organisme : Spanish Foundation of Rheumatology
ID : 17/EM253/0201
Informations de copyright
© 2023 The Authors. International Journal of Rheumatic Diseases published by Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.
Références
Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020;16:380-390. doi:10.1038/s41584-020-0441-1
Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey, 2007-2016. Arthritis Rheumatol. 2019;71:991-999. doi:10.1002/art.40807
Lim SY, Lu N, Oza A, et al. Trends in gout and rheumatoid arthritis hospitalizations in the United States, 1993-2011. JAMA. 2016;315:2345-2347. doi:10.1001/jama.2016.3517
Benavent D, Peiteado D, Martinez-Huedo MÁ, Hernandez-Hurtado M, Balsa A, de Miguel E. Healthcare-related impact of gout in hospitalized patients in Spain. Sci Rep. 2021;11:13287. doi:10.1038/s41598-021-92673-3
Fisher MC, Rai SK, Lu N, Zhang Y, Choi HK. The unclosing premature mortality gap in gout: a general population-based study. Ann Rheum Dis. 2017;76:1289-1294. doi:10.1136/annrheumdis-2016-210588
Khanna PP, Perez-Ruiz F, Maranian P, Khanna D. Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short Form-36 is responsive to change in chronic gout. Rheumatology (Oxford). 2011;50:740-745. doi:10.1093/rheumatology/keq346
Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76:29-42. doi:10.1136/annrheumdis-2016-209707
Pascual E, Sivera F. Why is gout so poorly managed? Ann Rheum Dis. 2007;66:1269-1270. doi:10.1136/ard.2007.078469
Jatuworapruk K, Grainger R, Dalbeth N, Taylor WJ. Regular pre-admission urate-lowering therapy and serum urate testing are associated with a shorter hospital length of stay in people with gout: a nation-wide population-based cohort study. Int J Rheum Dis. 2022;25:154-162. doi:10.1111/1756-185X.14250
Grassi W, Meenagh G, Pascual E, Filippucci E. “Crystal clear”-sonographic assessment of gout and calcium pyrophosphate deposition disease. Semin Arthritis Rheum. 2006;36:197-202. doi:10.1016/j.semarthrit.2006.08.001
Bardin T, Nguyen QD, Tran KM, et al. A cross-sectional study of 502 patients found a diffuse hyperechoic kidney medulla pattern in patients with severe gout. Kidney Int. 2021;99:218-226. doi:10.1016/j.kint.2020.08.024
Terslev L, Gutierrez M, Schmidt WA, et al. Ultrasound as an outcome measure in gout. A validation process by the OMERACT ultrasound working group. J Rheumatol. 2015;42:2177-2181. doi:10.3899/jrheum.141294
Christiansen SN, Østergaard M, Slot O, Fana V, Terslev L. Ultrasound for the diagnosis of gout-the value of gout lesions as defined by the outcome measures in rheumatology ultrasound group. Rheumatology. 2021;60:239-249. doi:10.1093/rheumatology/keaa366
Ottaviani S, Allard A, Bardin T, Richette P. An exploratory ultrasound study of early gout. Clin Exp Rheumatol. 2011;29:816-821.
De Miguel E, Puig JG, Castillo C, Peiteado D, Torres RJ, Martín-Mola E. Diagnosis of gout in patients with asymptomatic Hyperuricaemia: a pilot ultrasound study. Ann Rheum Dis. 2012;71:157-158. doi:10.1136/ard.2011.154997
Chowalloor P, Raymond WD, Cheah P, Keen H. The burden of subclinical intra-articular inflammation in gout. Int J Rheum Dis. 2020;23:661-668. doi:10.1111/1756-185X.13811
Hammer HB, Karoliussen L, Terslev L, Haavardsholm EA, Kvien TK, Uhlig T. Ultrasound shows rapid reduction of crystal depositions during a treat-to-target approach in gout patients: 12-month results from the NOR-gout study. Ann Rheum Dis. 2020;79:1500-1505. doi:10.1136/annrheumdis-2020-217392
Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med. 2012;125:679-687.e1. doi:10.1016/j.amjmed.2011.09.033
Disveld IJM, Zoakman S, Jansen TLTA, et al. Crystal-proven gout patients have an increased mortality due to cardiovascular diseases, cancer, and infectious diseases especially when having tophi and/or high serum uric acid levels: a prospective cohort study. Clin Rheumatol. 2019;38:1385-1391. doi:10.1007/s10067-019-04520-6
Dang W, Zhao L, Wang J, Xu D, Liu J, You L. Association between serum uric acid levels of patients with gout and their complications and examination fees: a cross-sectional analysis. Int J Rheum Dis. 2023;26:673-681. doi:10.1111/1756-185X.14609
Bardin T, Letavernier E, Correas J-M. The gouty kidney: a reappraisal. Gout Urate Cryst Depos Dis. 2023;1:25-36. doi:10.3390/gucdd1010004
Klauser AS, Halpern EJ, Strobl S, et al. Dual-energy computed tomography detection of cardiovascular monosodium urate deposits in patients with gout. JAMA Cardiol. 2019;4:1019-1028. doi:10.1001/jamacardio.2019.3201
Pascart T, Carpentier P, Choi HK, et al. Identification and characterization of peripheral vascular color-coded DECT lesions in gout and non-gout patients: the VASCURATE study. Semin Arthritis Rheum. 2021;51:895-902. doi:10.1016/j.semarthrit.2021.06.009
Dalbeth N, Alhilali M, Riordan P, et al. Vascular deposition of monosodium urate crystals in gout: analysis of cadaveric tissue by dual-energy computed tomography and compensated polarizing light microscopy. Arthritis Rheumatol. 2022;74:1295-1296. doi:10.1002/art.42066
Perez-Ruiz F, Martínez-Indart L, Carmona L, Herrero-Beites AM, Pijoan JI, Krishnan E. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis. 2014;73:177-182. doi:10.1136/annrheumdis-2012-202421
Disveld IJM, Fransen J, Rongen GA, et al. Crystal-proven gout and characteristic gout severity factors are associated with cardiovascular disease. J Rheumatol. 2018;45:858-863. doi:10.3899/jrheum.170555
Calabuig I, Martínez-Sanchis A, Andrés M. Sonographic tophi and inflammation are associated with carotid atheroma plaques in gout. Front Med (Lausanne). 2021;8:795984. doi:10.3389/fmed.2021.795984
Pascart T, Grandjean A, Norberciak L, et al. Ultrasonography and dual-energy computed tomography provide different quantification of urate burden in gout: results from a cross-sectional study. Arthritis Res Ther. 2017;19:171. doi:10.1186/s13075-017-1381-2
Neogi T, Jansen TLTA, Dalbeth N, et al. 2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol. 2015;67:2557-2568. doi:10.1002/art.39254
von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull World Health Organ. 2007;85:867-872. doi:10.2471/blt.07.045120
Stevens PE, Levin A, Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and Management of Chronic Kidney Disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158:825-830. doi:10.7326/0003-4819-158-11-201306040-00007
Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med. 2017;15:123. doi:10.1186/s12916-017-0890-9
Glassock RJ, Rule AD. Aging and the kidneys: anatomy, physiology and consequences for defining chronic kidney disease. Nephron. 2016;134:25-29. doi:10.1159/000445450
Ogdie A, Taylor WJ, Neogi T, et al. Performance of ultrasound in the diagnosis of gout in a multicenter study: comparison with monosodium urate monohydrate crystal analysis as the gold standard. Arthritis Rheumatol. 2017;69:429-438. doi:10.1002/art.39959
Naredo E, Uson J, Jiménez-Palop M, et al. Ultrasound-detected musculoskeletal urate crystal deposition: which joints and what findings should Be assessed for diagnosing gout? Ann Rheum Dis. 2014;73:1522-1528. doi:10.1136/annrheumdis-2013-203487
Thabane L, Mbuagbaw L, Zhang S, et al. A tutorial on sensitivity analyses in clinical trials: the what, why, when and how. BMC Med Res Methodol. 2013;13:92. doi:10.1186/1471-2288-13-92
Sivera F, Andrés M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis. 2014;73:328-335. doi:10.1136/annrheumdis-2013-203325
Pascart T, Latourte A, Flipo R-M, et al. 2020 recommendations from the French Society of Rheumatology for the management of gout: urate-lowering therapy. Joint Bone Spine. 2020;87:395-404. doi:10.1016/j.jbspin.2020.05.002
Peiteado D, De Miguel E, Villalba A, Ordóñez MC, Castillo C, Martín-Mola E. Value of a short four-joint ultrasound test for gout diagnosis: a pilot study. Clin Exp Rheumatol. 2012;30:830-837.
Bhadu D, Das SK, Wakhlu A, Dhakad U, Sharma M. Ultrasonographic detection of double contour sign and hyperechoic aggregates for diagnosis of gout: two sites examination is as good as six sites examination. Int J Rheum Dis. 2018;21:523-531. doi:10.1111/1756-185X.13235
Singh JA, Budzik J-F, Becce F, Pascart T. Dual-energy computed tomography vs ultrasound, alone or combined, for the diagnosis of gout: a prospective study of accuracy. Rheumatology. 2021;60:4861-4867. doi:10.1093/rheumatology/keaa923
Pascart T, Ramon A, Ottaviani S, et al. Association of specific comorbidities with monosodium urate crystal deposition in urate-lowering therapy-naive gout patients: a cross-sectional dual-energy computed tomography study. J Clin Med. 2020;9:E1295. doi:10.3390/jcm9051295
Marty-Ané A, Norberciak L, Andrès M, et al. Crystal deposition measured with dual-energy computed tomography: association with mortality and cardiovascular risks in gout. Rheumatology. 2021;60:4855-4860. doi:10.1093/rheumatology/keaa920
Stamp LK, Farquhar H, Pisaniello HL, et al. Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities. Nat Rev Rheumatol. 2021;17:633-641. doi:10.1038/s41584-021-00657-4
Saag KG, Whelton A, Becker MA, MacDonald P, Hunt B, Gunawardhana L. Impact of febuxostat on renal function in gout patients with moderate-to-severe renal impairment. Arthritis Rheumatol. 2016;68:2035-2043. doi:10.1002/art.39654
Vargas-Santos AB, Peloquin CE, Zhang Y, Neogi T. Association of chronic kidney disease with Allopurinol use in gout treatment. JAMA Intern Med. 2018;178:1526-1533. doi:10.1001/jamainternmed.2018.4463
Vazquez-Mellado J, Peláez-Ballestas I, Burgos-Vargas R, et al. Improvement in OMERACT domains and renal function with regular treatment for gout: a 12-month follow-up cohort study. Clin Rheumatol. 2018;37:1885-1894. doi:10.1007/s10067-018-4065-7
Novella-Navarro M, Cabrera-Alarcon JL, Diaz-Torne C, et al. A treat-to-target approach for gout confers renoprotective effect in patients with chronic kidney disease stage 3. Rheumatol Int. 2020;40:1081-1087. doi:10.1007/s00296-020-04517-4
Whelton A, Macdonald PA, Zhao L, Hunt B, Gunawardhana L. Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol. 2011;17:7-13. doi:10.1097/RHU.0b013e318204aab4
Chung T-T, Yu K-H, Kuo C-F, et al. Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients. Arthritis Res Ther. 2019;21:210. doi:10.1186/s13075-019-1993-9
Pérez Ruiz F, Richette P, Stack AG, Karra Gurunath R, García de Yébenes MJ, Carmona L. Failure to reach uric acid target of <0.36 mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality. RMD Open. 2019;5:e001015. doi:10.1136/rmdopen-2019-001015
Kim SC, Schneeweiss S, Choudhry N, Liu J, Glynn RJ, Solomon DH. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study. Am J Med. 2015;128:653.e7-653.e16. doi:10.1016/j.amjmed.2015.01.013
Yen F-S, Hsu C-C, Li H-L, Wei JC-C, Hwu C-M. Urate-lowering therapy may prevent the development of coronary artery disease in patients with gout. Front Med (Lausanne). 2020;7:63. doi:10.3389/fmed.2020.00063
Tardif J-C, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381:2497-2505. doi:10.1056/NEJMoa1912388
Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383:1838-1847. doi:10.1056/NEJMoa2021372